A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy

Date Added
December 8th, 2020
PRO Number
Pro00102184
Researcher
James Oates

List of Studies


Keywords
Autoimmune disease, Lupus
Summary

The purpose of this study is to determine if investigational (not FDA approved) drug AMG570 can be an effective treatment for patients with Systemic lupus erythematosus (SLE) that are not responding well to their current standard of care therapy. This study will compare 3 dose levels with placebo (A placebo looks like the study drug, but the injection does not contain the active ingredient) to determine the ideal therapeutic dose. You will have 32 scheduled visits. Your participation in this study will last approximately 1 year and 5 months consisting of the following: Screening (2 visits); Treatment will be administered (by injection) every 2 weeks for 52 weeks; and safety follow-up (16 weeks).

Institution
MUSC
Recruitment Contact
Traeannah Chisolm
843-792-4296
chisoltr@musc.edu



-- OR --